CG
TCRR

Cutler Group’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History

Cutler Group’s Portfolio TCRR Stock Details TCRR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-1,300
Closed -$2K – 6525
2020
Q4 		$2K Buy
1,300
+100
+8% +$2.53K ﹤0.01% 4303
2020
Q3 		$13K Sell
1,200
-100
-8% -$1.76K ﹤0.01% 2818
2020
Q2 		$6K Buy
+1,300
New +$15K ﹤0.01% 3245

Cutler Group's TCRR Position: Q2 2023 in Review

Cutler Group sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q2 2023, closing a stake of 1,000 shares — an estimated $1K sold.

Cutler Group first reported a position in TCRR in Q2 2020 and held it in 11 quarters. The position peaked at $49K in Q4 2020. 0 funds tracked by Wall St. Rank hold TCRR as of Q2 2023.

  • Cutler Group reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Cutler Group sold 1,000 TCR2 Therapeutics Inc. Common Stock shares in Q2 2023, an estimated $1K.
  • Cutler Group first reported a position in TCR2 Therapeutics Inc. Common Stock in Q2 2020 and held it in 11 quarters.
  • Cutler Group's TCR2 Therapeutics Inc. Common Stock position peaked at $49K in Q4 2020.
  • 0 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q2 2023.

Based on Cutler Group's 13F filing for Q2 2023, filed 18 Jul 2023.